JP2009535422A - 血管作動薬を含有する持続放出性眼内インプラント - Google Patents

血管作動薬を含有する持続放出性眼内インプラント Download PDF

Info

Publication number
JP2009535422A
JP2009535422A JP2009510011A JP2009510011A JP2009535422A JP 2009535422 A JP2009535422 A JP 2009535422A JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009510011 A JP2009510011 A JP 2009510011A JP 2009535422 A JP2009535422 A JP 2009535422A
Authority
JP
Japan
Prior art keywords
implant
eye
vasodilator
vasoactive
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009510011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535422A5 (https=
Inventor
ジョン・イー・ドネロ
ロン・ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2009535422A publication Critical patent/JP2009535422A/ja
Publication of JP2009535422A5 publication Critical patent/JP2009535422A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
JP2009510011A 2006-05-04 2007-05-01 血管作動薬を含有する持続放出性眼内インプラント Pending JP2009535422A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/417,420 US20070260203A1 (en) 2006-05-04 2006-05-04 Vasoactive agent intraocular implant
PCT/US2007/067883 WO2007130945A1 (en) 2006-05-04 2007-05-01 A sustained-release intraocular implant comprising a vasoactive agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013170156A Division JP2014014694A (ja) 2006-05-04 2013-08-20 血管拡張薬を含有する持続放出性眼内インプラント

Publications (2)

Publication Number Publication Date
JP2009535422A true JP2009535422A (ja) 2009-10-01
JP2009535422A5 JP2009535422A5 (https=) 2010-06-24

Family

ID=38508941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009510011A Pending JP2009535422A (ja) 2006-05-04 2007-05-01 血管作動薬を含有する持続放出性眼内インプラント
JP2013170156A Pending JP2014014694A (ja) 2006-05-04 2013-08-20 血管拡張薬を含有する持続放出性眼内インプラント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013170156A Pending JP2014014694A (ja) 2006-05-04 2013-08-20 血管拡張薬を含有する持続放出性眼内インプラント

Country Status (8)

Country Link
US (1) US20070260203A1 (https=)
EP (1) EP2026764B1 (https=)
JP (2) JP2009535422A (https=)
AU (1) AU2007248143B2 (https=)
BR (1) BRPI0711311A2 (https=)
CA (1) CA2651300C (https=)
DK (1) DK2026764T3 (https=)
WO (1) WO2007130945A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516829A (ja) * 2021-04-30 2024-04-17 パフューズ セラピューティクス， インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US9849027B2 (en) 2007-11-08 2017-12-26 Alimera Sciences, Inc. Ocular implantation device
DE102008040786A1 (de) * 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CA3186189A1 (en) 2009-05-18 2010-11-25 Dose Medical Corporation Drug eluting ocular implant
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
CA2798084A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US20120276186A1 (en) * 2011-04-29 2012-11-01 Ghebremeskel Alazar N Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US8883189B2 (en) 2011-09-27 2014-11-11 The Regents Of The University Of Colorado, A Body Corporate Intraocular encapsulation of oxygenic bacteria
CN109602691A (zh) * 2013-02-15 2019-04-12 阿勒根公司 持续药物递送植入物
EP3677229A1 (en) 2014-05-29 2020-07-08 Glaukos Corporation Implants with controlled drug delivery features
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3442479B1 (en) 2016-04-20 2026-03-04 Glaukos Corporation Bioresorbable ocular drug delivery device
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3893918B1 (en) * 2018-12-10 2024-09-25 Rigshospitalet Vasodilators for use in the treatment of a retinal ischemic disorder
GB2601922B (en) 2019-06-27 2024-04-24 Layerbio Inc Ocular device drub delivery systems
WO2021087399A1 (en) 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
US12226452B2 (en) * 2020-03-04 2025-02-18 The Schepens Eye Research Institute, Inc. Polyhedrin-based slow release growth factor system for neuroprotection of retinal ganglion cell neurons
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CA3218251A1 (en) 2021-04-30 2022-11-03 Perfuse Therapeutics, Inc. Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110420A1 (de) * 2004-05-11 2005-11-24 Bayer Healthcare Ag Formulierungen mit kontrollierter wirkstofffreisetzung enthaltend vardenafil
WO2005110424A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable intraocular implants containing prostamides
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AU2002236495B2 (en) * 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
AP1893A (en) * 2000-12-01 2008-09-23 Osi Pharm Inc Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
US7468065B2 (en) * 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005110374A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8512738B2 (en) * 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2615360A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110424A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable intraocular implants containing prostamides
WO2005110362A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable ocular implants with long-term release characteristics
WO2005110420A1 (de) * 2004-05-11 2005-11-24 Bayer Healthcare Ag Formulierungen mit kontrollierter wirkstofffreisetzung enthaltend vardenafil
WO2006041942A2 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012026349; 今日の治療指針２００４年版 , 2004, ｐ．９８６ *
JPN6012026350; ＬＡＷＳ，Ｈ: 'Ｐｅｒｉｐｈｅｒａｌ　ｖａｓｏｄｉｌａｔｏｒｓ　ｉｎ　ｔｈｅ　ｔｒｅａｔｍｅｎｔ　ｏｆ　ｍａｃｕｌａｒ　ｄｅｇｅｎｅｒａｔｉｖｅ　ｃｈａｎｇｅｓ　ｉｎ　ｔｈｅ　ｅｙｅ' Ｃａｎａｄｉａｎ　Ｍｅｄｉｃａｌ　Ａｓｓｏｃｉａｔｉｏｎ　ｊｏｕｒｎａｌ Ｖｏｌ．９１，　Ｎｏ．７, 1964, ｐ．３２５-３３０ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516829A (ja) * 2021-04-30 2024-04-17 パフューズ セラピューティクス， インコーポレイテッド エンドセリンレセプターアンタゴニストを使用する眼疾患の処置

Also Published As

Publication number Publication date
EP2026764B1 (en) 2017-07-12
AU2007248143A1 (en) 2007-11-15
DK2026764T3 (en) 2017-10-23
US20070260203A1 (en) 2007-11-08
CA2651300C (en) 2015-09-15
WO2007130945A1 (en) 2007-11-15
AU2007248143B2 (en) 2012-11-08
JP2014014694A (ja) 2014-01-30
EP2026764A1 (en) 2009-02-25
BRPI0711311A2 (pt) 2011-12-06
CA2651300A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
AU2007248143B2 (en) A sustained-release intraocular implant comprising a vasoactive agent
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP5580832B2 (ja) 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
CA2565347C (en) Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
JP6511401B2 (ja) 持続型薬物送達インプラント
JP5552102B2 (ja) 長時間放出特性を有する生分解性眼インプラント
JP5826872B2 (ja) 眼内使用のための環状脂質インプラントの製造法
JP5982360B2 (ja) 眼房内ビマトプロスト注入物による眼圧低下
US8529927B2 (en) Alpha-2 agonist polymeric drug delivery systems
CN1950091A (zh) 含前列腺酰胺的可生物降解眼内植入物
TW200538135A (en) Extended therapeutic effect ocular implant treatments
CN102497865A (zh) 用于治疗眼部病症的眼内缓释药物递送系统和方法
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
JP2007535564A (ja) 抗興奮毒性剤持続放出眼内インプラントおよび関連方法
AU2011213904B2 (en) Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120522

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120821

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121019

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130820